Recruiting PHASE2 INTERVENTIONAL 2-arm NCT06413992

Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer

Efficacy and Safety of Camrelizumab Plus Albumin-bound Paclitaxel/Carboplatin Followed by Camrelizumab With or Without Fluzoparib Maintenance Therapy for TP-53 Mutated Recurrent or Metastatic Endometrial Cancer: A Phase II Trial

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Conditions Endometrial Carcinoma Recurrent or Metastatic TP53 Mutation

Interventions Camrelizumab Carboplatin Carboplatin injection External irradiation Fluzoparib paclitaxel (albumin bound)

Updated 3 times since 2024 Last updated: May 10, 2024 Started: May 10, 2024 Primary completion: Jun 1, 2026 Completion: Jun 1, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Endometrial Carcinoma and Recurrent or Metastatic, this trial is actively recruiting participants. The trial is conducted by Cancer Institute and Hospital, Chinese Academy of Medical Sciences and has accumulated 3 data snapshots since 2024. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Jun 2024 — Jul 2024 [monthly]

Recruiting PHASE2

First recorded

May 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Data source: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China